A Jiangsu Hengrui Medicine Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. patent describes new fibroblast activation protein-α (FAP-α) inhibitors comprising a chelator and a radiolabeled compound potentially useful for the diagnosis and treatment of cancer.

Glenmark Pharmaceuticals Ltd. has synthesized substituted biphenyl compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

The Agency for Science Technology & Research (A*STAR) Bioprocessing Technology Institute has patented 3C-like proteinase (3CLpro; Mpro; nsp5) (coronavirus) inhibitors.

Benobio Co. Ltd. has discovered new benzothiophene derivatives acting as bromodomain-containing protein 2 (BD1 domain) (Brd2 BD1) inhibitors reported to be useful for the treatment of cancer.

Elgen Therapeutics Inc. has patented new 4-chromanone derivative proteolysis targeting chimera (PROTAC) compounds comprising a von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled with a WD repeat-containing protein 5 (WDR5; BIG3)-targeting moiety through a linker.

Work at Tango Therapeutics Inc. has led to the identification of new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

A Genentech Inc. patent discloses compounds which could potentially treat cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized new compounds.

Merck Sharp & Dohme LLC has patented new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Arcus Biosciences Inc. has synthesized new E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.